Technology Commercialization Panel
The Technology Commercialization Panel (TCP) is a group of market experts, successful entrepreneurs, and experienced investors that Tech Transfer meets with on a bimonthly basis. The TCP provides Tech Transfer with valuable commercial feedback on APL intellectual property and industry contacts to improve the impact of our commercialization efforts.
With an extensive record in the field of technology, Irfan Ali has a unique combination of executive management, technical, and marketing skills. A professed technologist, he has a passion for bringing new, innovative technology to the market in the form of products and solutions that address complex, contemporary problems. Prior to joining ARC, Irfan was president and CEO of Lambda OpticalSystems, a late-stage, venture-backed start-up building high-end optical networking equipment. Before Lambda, he was president of CommWorks Corporation, a 3Com company. Irfan received an M.S. in electrical engineering and an M.B.A. from Southern Methodist University. He was also a founding member of the ATM Forum.
Stephen Auvil is the executive vice president for Operations and Programs at the Maryland Technology Development Corporation (TEDCO). In this role, he is responsible for overseeing TEDCO’s administrative, technology transfer, and entrepreneurial support programs. Prior to TEDCO, Stephen worked in academic technology transfer at the University of Maryland, Baltimore County (UMBC) and at Johns Hopkins University School of Medicine. Stephen’s early career included positions with medical device companies and in academic research. He graduated with a B.S. in biology and engineering science from Loyola University in Maryland; he also earned an M.B.A. from the University of Baltimore and an M.S. in biotechnology from the Johns Hopkins University.
Chuck Cullen is a general partner at Grotech Ventures, an early-stage venture capital firm. He brings 20 years of experience as an early-stage investor and board member across a broad spectrum of information technology, software, security, and tech-leveraged services businesses. Chuck has also served as a judge for a number of entrepreneurial programs, including the Invest Maryland Challenge, Ernst & Young’s Entrepreneur of the Year program, and the Maryland Incubator of the Year program. Before joining Grotech, Chuck served as the chief financial officer of Avatech Solutions, Inc., an early-stage IT solutions provider in the design automation market. He previously worked as a management consultant on Fortune 500 engagements for A.T. Kearney, Inc., practiced law with Hogan and Hartson, and began his career in public accounting as a CPA with Ernst & Young. He received his J.D. from the University of Notre Dame Law School and his M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
Steve Falk is the chief engineer for Maternal Infant Care at GE Healthcare. He has been with the company for 28 years in a variety of roles, including senior engineer, engineering manager, lead program engineer, engineering director, chief technology officer, and chief engineer. Steve has been integrally involved with all phases of product development, including voice of customer, business development, business model generation, design, verification, validation, and production transfer. He also serves as the Patent Evaluation Board leader. Steve has a bachelor’s degree in engineering from the University of Pennsylvania and a master’s degree in engineering from The Catholic University of America.
Dr. Chris Geddes has extensive experience in fluorescence spectroscopy, particularly in fluorescence sensing and metal-fluorophore interactions. Chris is internationally known in fluorescence and plasmonics, and the development of the metal-enhanced fluorescence (MEF) and related plasmon-fluorescence technologies is widely attributed to his laboratory. He is director of the Institute of Fluorescence, a department within the University of Maryland, Baltimore County (UBMC), which focuses on the nano-bio-technological applications of fluorescence. Chris holds more than 100 patents in the fields of fluorescence and plasmonics.
Jim Goepel is Fathom Cyber’s CEO and general counsel. He worked in a variety of technical roles for large corporations, start-ups, and Congress before attending law school. In his legal career, Jim worked for several years as an outside attorney and patent agent for a large law firm, where he advised individuals, start-ups, and Fortune 100 corporations on a wide range of legal matters. He is active in defining the technical attributes of Fathom Cyber’s flagship offerings, ensures that the company’s intellectual property is well protected, and provides legal guidance in other areas as well.
Dr. Albine Martin brings over 25 years of operating and commercialization experience within three public companies representing the biotechnology, diagnostics, therapeutics, and life sciences sectors. She provides leadership to advance technologies from bench to market in her role as executive in residence at Johns Hopkins University and Biohealth Innovation. She has developed translational strategies and facilitated seed funding for technologies within digital health, diagnostics, medical devices, research tools, and therapeutics. As chief operating officer of Precision Biologics (a clinical-stage oncology company), Dr. Martin led integration of clinical development with a companion diagnostic strategy. As vice president of Compugen (CGEN), she built a revenue model incorporating consumable assets with big data and managed strategic alliances to translate computational discoveries. During her tenure at Life Technologies (LIFE), she led a global portfolio as senior business director and managed joint ventures and expansion within the Asia-Pacific region. She has collaborated with the FDA/Center for Biologics Evaluation and Research to develop compliance standards and commercialization strategies for ancillary products and devices within the cellular and gene therapy arena. Dr. Martin has led start-up innovation through the BLA approval and commercialization of the first HPV diagnostic at Digene Diagnostics and, more recently, the advancement of an HIV-1 persistence assay portfolio with Accelevir Diagnostics. She is a member of New Dominion Angels and an angel investor. She supports the start-up region through her role as reviewer on seed funding programs, including the National Science Foundation Small Business Innovation Research (SBIR) seed fund. Dr. Martin holds a Ph.D. from the University of Maryland, served as a Staff Fellow at the National Institutes of Health, holds a Certificate of Financial Management from Cornell University, and is a graduate of the Program on Leadership and Strategy in Pharmaceuticals and Biotech at the Harvard Business School.
Jay Pasricha received his training in gastroenterology at Johns Hopkins Hospital. In August 2007, he was appointed as chief of gastroenterology at Stanford University of Medicine, a position he held until assuming his current position back at Johns Hopkins in July 2012. Jay has served on the National Commission on Digestive Diseases, which was appointed by Congress to provide a “road map” for progress in gastrointestinal disorders. He is also the founding chair of the Center for Gastrointestinal Innovation and Technology, a body created by the American Gastroenterological Association. Jay holds more than 50 patents and has cofounded several companies within both the medtech and biotech GI space, including Apollo Endosurgery, Enterastim, First Aid Shot Therapeutics (FAST), Neurogastrx, Orphomed, and Glyscend.
Rebecca Ranich is an energy industry executive with deep roots in capital intense energy supply and demand infrastructure and energy technologies. Over her career, she has led transformational business initiatives, forged global strategic alliances, and led new market ventures in energy and infrastructure sectors. She is a member of the supervisory board for Uniper SE and also serves on the advisory board of Yet Analytics, Inc.
Gus Simiao is an entrepreneur in residence at Data Point Capital. Most recently, he was principal at CEVG, an angel investment group focused on early-stage companies. Previously, Gus was CEO of Electric Field Solutions (EFS), a spin-out from the University of Michigan that developed and marketed an innovative electric field sensor. EFS was acquired by Willbros Group, returning 20× on invested capital. Before EFS, Gus was CEO of Vortex Hydro Energy, which developed an innovative technology also licensed from the University of Michigan. He raised $4M to fund the company from the Department of Defense, Department of Energy, National Science Foundation, and angel investors. Although the technology didn’t pan out, the venture resulted in an excellent learning experience. Previously, Gus was a management consultant with the Boston Consulting Group. He holds an M.B.A. from the University of Michigan Ross School of Business and a B.S. in mechanical engineering with honors from the University of Toledo.
Kathryn Stewart is founder and managing director of Cranbrook Capital, which provides seed and early-stage capital to emerging tech-focused companies. The firm also invests in public and private equity. Previously, Kathryn was a managing director at Baltimore-based Alex. Brown and, post-acquisition, at Deutsche Bank.
Kathryn is a board member of Baltimore-based Passive Capital Management and a board observer at DC-based HomeSnap. She serves on both the Robert H. Smith School of Business advisory board and the Dingman board of advisors at the University of Maryland. She is active with Wharton’s Entrepreneurship Program at the University of Pennsylvania. She is also a trustee of the Maryland/DC Chapter of the Nature Conservancy. She is a past board member at the Stone Ridge School of the Sacred Heart, where she currently sits on the Finance and Investment Committee.
Kathryn holds an M.B.A. in finance from the Wharton School at the University of Pennsylvania and a B.S. in electrical engineering from Michigan State University.
Robert Storey is the managing director of The MVR Company, which focuses on the assessment and creation of new ventures, with a particular emphasis on medical technologies. He is also the managing partner of The LaunchPort™ in Baltimore, Maryland, an innovative manufacturing accelerator for companies entering the regulatory approval process and preparing for commercial adoption. He is chairman and board member for a number of early-stage companies in orthopedics and cardiology.
Gil Tadmor is the managing principal at Radiant Digital Ventures Studio focusing on investment and advising for early-stage technology start-ups. A highly respected industry leader and entrepreneur with an extensive record of transforming concepts into working products, Gil has a unique combination of executive management, technical expertise, and go-to-market skills that have contributed to the success of many technology teams and entrepreneurs ranging in size from a few individuals to large groups upward of 500 personnel. With a passion for innovating and empowering, Gil has been mentoring and advising entrepreneurs and technologists in aligning their creative ideas with the right products and solutions while addressing current needs in target markets. Before launching Radiant Digital Ventures Studio, Gil held numerous chief technology officer positions in public- and private-sector companies. He served as a mentor for the entrepreneurship program at the University of Maryland’s Dingman Center for Entrepreneurship. He was also an original executive member of a venture-backed start-up building next-generation optical networking equipment, culminating in a $1.14B IPO. Gil has a master’s degree in computer science from Johns Hopkins University and a bachelor’s degree in mechanical engineering from The Technion, Israel’s Institute of Technology in Haifa.